Systemic therapy for metastatic renal cell carcinoma in the first-line setting: a systematic review and network meta-analysis

PURPOSE: Management of metastatic renal cell cancer (mRCC) has undergone a paradigm shift with immune-checkpoint inhibitors (ICI) in the first-line setting. However, direct comparative data are inadequate to inform treatment decisions. Therefore, we aimed to assess first-line therapy for mRCC and in...

Descripción completa

Detalles Bibliográficos
Autores principales: Mori, Keiichiro, Mostafaei, Hadi, Miura, Noriyoshi, Karakiewicz, Pierre I., Luzzago, Stefano, Schmidinger, Manuela, Bruchbacher, Andreas, Pradere, Benjamin, Egawa, Shin, Shariat, Shahrokh F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7889529/
https://www.ncbi.nlm.nih.gov/pubmed/32757054
http://dx.doi.org/10.1007/s00262-020-02684-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7889529/
https://www.ncbi.nlm.nih.gov/pubmed/32757054
http://dx.doi.org/10.1007/s00262-020-02684-8

Ejemplares similares